Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SM-1 for Transient Insomnia
NCT03338764Phase 3Withdrawn
- Sponsor
- Sequential Medicine Ltd.
- Start
- May 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
A Phase 3 trial of SM-1 in Insomnia, sponsored by Sequential Medicine Ltd.. Planned start May 2023; status: withdrawn.
02
Drugs
SM-1
03
Conditions
Insomnia
Beyond the preview
Go deeper on NCT03338764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03338764.